In vitro inhibitory activities of selected Australian medicinal plant extracts against protein glycation, angiotensin converting enzyme (ACE) and digestive enzymes linked to type II diabetes.

Publisher: BioMed Central Country of Publication: England NLM ID: 101088661 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6882 (Electronic) Linking ISSN: 14726882 NLM ISO Abbreviation: BMC Complement Altern Med Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-2019]

Angiotensin-Converting Enzyme Inhibitors*/chemistry ; Angiotensin-Converting Enzyme Inhibitors*/pharmacology ; Glycoside Hydrolase Inhibitors*/chemistry ; Glycoside Hydrolase Inhibitors*/pharmacology ; Plant Extracts*/chemistry ; Plant Extracts*/pharmacology; Diabetes Mellitus, Type 2/*enzymology ; Plants, Medicinal/*chemistry ; alpha-Amylases/*antagonists & inhibitors; Australia ; Flavonoids ; Humans ; Medicine, Traditional ; Phenols

Background: There is a need to develop potential new therapies for the management of diabetes and hypertension. Australian medicinal plants collected from the Kuuku I'yu (Northern Kaanju) homelands, Cape York Peninsula, Queensland, Australia were investigated to determine their therapeutic potential. Extracts were tested for inhibition of protein glycation and key enzymes relevant to the management of hyperglycaemia and hypertension. The inhibitory activities were further correlated with the antioxidant activities.
Methods: Extracts of five selected plant species were investigated: Petalostigma pubescens, Petalostigma banksii, Memecylon pauciflorum, Millettia pinnata and Grewia mesomischa. Enzyme inhibitory activity of the plant extracts was assessed against α-amylase, α-glucosidase and angiotensin converting enzyme (ACE). Antiglycation activity was determined using glucose-induced protein glycation models and formation of protein-bound fluorescent advanced glycation endproducts (AGEs). Antioxidant activity was determined by measuring the scavenging effect of plant extracts against 1, 1-diphenyl-2-picryl hydrazyl (DPPH) and using the ferric reducing anti-oxidant potential assay (FRAP). Total phenolic and flavonoid contents were also determined.
Results: Extracts of the leaves of Petalostigma banksii and P. pubescens showed the strongest inhibition of α-amylase with IC 50 values of 166.50 ± 5.50 μg/mL and 160.20 ± 27.92 μg/mL, respectively. The P. pubescens leaf extract was also the strongest inhibitor of α-glucosidase with an IC 50 of 167.83 ± 23.82 μg/mL. Testing for the antiglycation potential of the extracts, measured as inhibition of formation of protein-bound fluorescent AGEs, showed that P. banksii root and fruit extracts had IC 50 values of 34.49 ± 4.31 μg/mL and 47.72 ± 1.65 μg/mL, respectively, which were significantly lower (p < 0.05) than other extracts. The inhibitory effect on α-amylase, α-glucosidase and the antiglycation potential of the extracts did not correlate with the total phenolic, total flavonoid, FRAP or DPPH. For ACE inhibition, IC 50 values ranged between 266.27 ± 6.91 to 695.17 ± 15.38 μg/mL.
Conclusions: The tested Australian medicinal plant extracts inhibit glucose-induced fluorescent AGEs, α-amylase, α-glucosidase and ACE with extracts of Petalostigma species showing the most promising activity. These medicinal plants could potentially be further developed as therapeutic agents in the treatment of hyperglycaemia and hypertension.

J Biochem Mol Toxicol. 2009 Sep-Oct;23(5):364-72. (PMID: 19827132)
Eur J Pharmacol. 2010 Apr 25;632(1-3):103-9. (PMID: 20122920)
Food Chem Toxicol. 2011 Jul;49(7):1521-9. (PMID: 21443916)
Curr Diabetes Rev. 2012 Mar;8(2):92-108. (PMID: 22268395)
Biol Res Nurs. 2012 Jan;14(1):90-7. (PMID: 21278166)
Food Chem. 2012 Sep 15;134(2):1011-9. (PMID: 23107721)
Adv Pharmacol Sci. 2015;2015:410675. (PMID: 26798334)
J Ethnopharmacol. 2010 Oct 28;132(1):340-3. (PMID: 20633620)
Am J Physiol Cell Physiol. 2008 Oct;295(4):C849-68. (PMID: 18684987)
Biomed Res Int. 2015;2015:403291. (PMID: 25954749)
Circulation. 2006 Aug 8;114(6):597-605. (PMID: 16894049)
BMC Complement Altern Med. 2012 Sep 29;12:165. (PMID: 23020844)
J Agric Food Chem. 2008 Jun 25;56(12):4386-92. (PMID: 18522404)
BMC Complement Altern Med. 2013 May 29;13:118. (PMID: 23718315)
J Ethnopharmacol. 2009 Jan 21;121(2):278-81. (PMID: 19041700)
J Ethnopharmacol. 2011 Jun 22;136(2):305-8. (PMID: 21570455)
J Med Food. 2014 Oct;17(10):1151-7. (PMID: 25084312)
J Ethnopharmacol. 2010 Feb 3;127(2):235-41. (PMID: 19932161)
J Integr Med. 2016 Mar;14(2):84-99. (PMID: 26988430)
Life Sci. 2013 Feb 27;92(3):187-92. (PMID: 23270944)
Pharmacogn Mag. 2015 May;11(Suppl 1):S190-208. (PMID: 26109767)
BMC Complement Altern Med. 2015 Feb 05;15:8. (PMID: 25652009)
J Pharm Pharm Sci. 2013;16(2):259-71. (PMID: 23958195)
J Diabetes Metab Disord. 2014 Dec 02;13(1):114. (PMID: 25506585)
Hypertension. 2013 May;61(5):943-7. (PMID: 23595139)
J Ethnopharmacol. 1998 Oct;62(3):247-50. (PMID: 9849636)
Evid Based Complement Alternat Med. 2012;2012:632763. (PMID: 22701507)
Molecules. 2011 Dec 08;16(12 ):10214-26. (PMID: 22158590)
Lancet. 2006 Aug 12;368(9535):555-6. (PMID: 16905000)
Pharmacogn Rev. 2010 Jul;4(8):118-26. (PMID: 22228951)
Biochem Biophys Res Commun. 1999 Apr 13;257(2):251-8. (PMID: 10198198)
Carbohydr Res. 1984 Dec 1;134(2):191-204. (PMID: 6099220)
Anal Biochem. 1996 Jul 15;239(1):70-6. (PMID: 8660627)
Drug Res (Stuttg). 2015 Jun;65(6):296-9. (PMID: 25607746)
BMC Complement Altern Med. 2012 Jul 31;12:110. (PMID: 22849553)
Expert Opin Ther Targets. 2012 Mar;16(3):269-97. (PMID: 22360606)
Phytochemistry. 2006 Aug;67(16):1708-15. (PMID: 16298402)
Hypertens Res. 2013 Jul;36(7):570-9. (PMID: 23552514)
Treat Endocrinol. 2002;1(2):105-16. (PMID: 15765626)
BMC Complement Altern Med. 2012 Jun 19;12 :77. (PMID: 22713130)
J Asian Nat Prod Res. 2012;14(2):186-95. (PMID: 22296161)
Arch Biochem Biophys. 2003 Nov 1;419(1):31-40. (PMID: 14568006)
Future Med Chem. 2013 May;5(7):733-6. (PMID: 23651086)
Pharmacogn Mag. 2014 Jan;10(Suppl 1):S37-49. (PMID: 24914307)
Food Funct. 2011 May;2(5):224-34. (PMID: 21779560)
J Dairy Res. 2006 May;73(2):178-86. (PMID: 16476177)
J Ethnopharmacol. 2008 Sep 2;119(1):109-16. (PMID: 18601990)
Physiol Res. 2004;53(2):131-42. (PMID: 15046548)
BMC Complement Altern Med. 2012 Oct 06;12:173. (PMID: 23038995)

Keywords: Aboriginal; Angiotensin converting enzyme; Antiglycation; Antioxidant activities; Flavonoids; Local knowledge; Phenolics; Traditional medicine; α-amylase; α-glucosidase

0 (Angiotensin-Converting Enzyme Inhibitors)
0 (Flavonoids)
0 (Glycoside Hydrolase Inhibitors)
0 (Phenols)
0 (Plant Extracts)
EC 3.2.1.1 (alpha-Amylases)

Date Created: 20161105 Date Completed: 20170216 Latest Revision: 20220410

20231215

PMC5095981

10.1186/s12906-016-1421-5

27809834